Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1994 2
1995 4
1996 8
1997 5
1998 4
1999 6
2000 8
2001 5
2002 11
2003 7
2004 5
2005 3
2006 7
2007 7
2008 8
2009 5
2010 11
2011 17
2012 9
2013 15
2014 14
2015 11
2016 10
2017 24
2018 14
2019 24
2020 36
2021 43
2022 35
2023 29
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Results by year

Filters applied: . Clear all
Page 1
MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential.
Bayley R, Ward C, Garcia P. Bayley R, et al. Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188407. doi: 10.1016/j.bbcan.2020.188407. Epub 2020 Aug 25. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32853735 Review.
Changes in these pathways can facilitate cancer development and as such targeting these processes represent an effective method to treat multiple cancer types. Alterations in gene expression have been identified in cancer cells including changes in MYBL2 …
Changes in these pathways can facilitate cancer development and as such targeting these processes represent an effective method to tr …
MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3.
Liu W, Shen D, Ju L, Zhang R, Du W, Jin W, Xiong K, Wang G, Qian K, Zhang Y, Xiao Y, Wang X. Liu W, et al. Oncogene. 2022 Oct;41(41):4606-4617. doi: 10.1038/s41388-022-02456-x. Epub 2022 Sep 7. Oncogene. 2022. PMID: 36071275
However, the biological function of MYBL2 in bladder cancer (BLCA) remains to be elucidated. Here, we first revealed that MYBL2 was elevated in BLCA tissues and significantly correlated with clinicopathological parameters and cancer-specific survival i …
However, the biological function of MYBL2 in bladder cancer (BLCA) remains to be elucidated. Here, we first revealed that M …
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, Azuma H, Kantoff PW, Sweeney CJ. Yoshikawa Y, et al. Mol Oncol. 2022 Dec;16(22):3994-4010. doi: 10.1002/1878-0261.13314. Epub 2022 Oct 2. Mol Oncol. 2022. PMID: 36087093 Free PMC article.
Using chromatin immunoprecipitation sequencing (ChIP-seq) of the LNCaP cell line (androgen-sensitive human prostate adenocarcinoma) with and without silenced KDM5D, MYBL2-binding sites were analyzed. Associations between MYBL2 mRNA expression and clinical outcomes w …
Using chromatin immunoprecipitation sequencing (ChIP-seq) of the LNCaP cell line (androgen-sensitive human prostate adenocarcinoma) with and …
Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene.
Chen X, Lu Y, Yu H, Du K, Zhang Y, Nan Y, Huang Q. Chen X, et al. Cell Cycle. 2021 Nov;20(21):2291-2308. doi: 10.1080/15384101.2021.1982494. Epub 2021 Sep 29. Cell Cycle. 2021. PMID: 34585645 Free PMC article.
MYBL2 has been demonstrated to be an oncogene in some cancers, but there is no pan-cancer analysis at the macro level. ...Moreover, we verified the function of MYBL2 in three cancer cells of glioma, breast cancers and liver cancers …
MYBL2 has been demonstrated to be an oncogene in some cancers, but there is no pan-cancer analysis at the macro level. …
PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer.
He Q, Ding Z, Chen T, Wu H, Song J, Xiang Z, Yang C, Wang S, Xiong B. He Q, et al. Front Oncol. 2023 Jul 18;13:1164070. doi: 10.3389/fonc.2023.1164070. eCollection 2023. Front Oncol. 2023. PMID: 37538116 Free PMC article.
Previously, we identified PFDN2 as a novel key gene in gastric cancer based on its differential expression between cancer and normal tissues. ...We further found that PFDN2 could promote cell cycle progression by promoting MYBL2 expression. Mechanistically, w …
Previously, we identified PFDN2 as a novel key gene in gastric cancer based on its differential expression between cancer and …
LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.
Mu X, Shen Z, Lin Y, Xiao J, Xia K, Xu C, Chen B, Shi R, Zhu A, Sun X, Tao T, Song X, Xuan Q. Mu X, et al. Oxid Med Cell Longev. 2022 May 2;2022:8693259. doi: 10.1155/2022/8693259. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35557985 Free PMC article.
It is known that the long noncoding RNAs (lncRNA) MALAT1 is associated with tumorigenesis and progression in various cancers; however, its functions and mechanisms in prostate cancer (PCa) initiation and progression are still unknown. ...Taken together, our research …
It is known that the long noncoding RNAs (lncRNA) MALAT1 is associated with tumorigenesis and progression in various cancers; however …
MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q, Wang M, Hu Y, Zhao E, Li J, Ren L, Wang M, Xu Y, Liang Q, Zhang D, Lai Y, Liu S, Peng X, Zhu C, Ye L. Li Q, et al. Theranostics. 2021 Mar 31;11(12):5794-5812. doi: 10.7150/thno.56604. eCollection 2021. Theranostics. 2021. PMID: 33897882 Free PMC article.
Rationale: Resistance to androgen-deprivation therapy (ADT) associated with metastatic progression remains a challenging clinical task in prostate cancer (PCa) treatment. Current targeted therapies for castration-resistant prostate cancer (CRPC) are not durable. ... …
Rationale: Resistance to androgen-deprivation therapy (ADT) associated with metastatic progression remains a challenging clinical task in pr …
Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G, Gong T, Wang Z, Wang Z, Lin X, Chen S, Sun C, Zhao W, Kong Y, Ai H, Yang H, Liu Y, Wu F, Kang J, Zhao S, Xiao X, Sun J, He A, Li Z. Chen G, et al. Cell Oncol (Dordr). 2022 Dec;45(6):1155-1167. doi: 10.1007/s13402-022-00705-5. Epub 2022 Sep 22. Cell Oncol (Dordr). 2022. PMID: 36136268
PURPOSE: Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal cancer (CRC) patients. However, chemoresistance-induced resistance is an essential cause for mortality. ...The data also revealed several putative drug resistant-driven genes (STMN1, VE …
PURPOSE: Oxaliplatin-based chemotherapy is a standard treatment for advanced colorectal cancer (CRC) patients. However, chemoresistan …
A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer.
Liu Q, Liu H, Huang X, Fan X, Xiao Z, Yan R, Yao J, An G, Ge Y, Miao J, Liu J. Liu Q, et al. Cancer Gene Ther. 2023 Jan;30(1):192-208. doi: 10.1038/s41417-022-00538-2. Epub 2022 Sep 23. Cancer Gene Ther. 2023. PMID: 36151333
As a downstream target of MYBL2, ATAD2 deletion significantly impaired MYBL2-driven cell proliferation. Intriguingly, ATAD2 silencing also fed back to destabilize the MYBL2 protein. The significant coexpression of MYBL2 and ATAD2 at both the bulk tissu …
As a downstream target of MYBL2, ATAD2 deletion significantly impaired MYBL2-driven cell proliferation. Intriguingly, ATAD2 si …
MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
Jiao M, Zhang F, Teng W, Zhou C. Jiao M, et al. Int J Gen Med. 2022 Mar 15;15:3003-3030. doi: 10.2147/IJGM.S351638. eCollection 2022. Int J Gen Med. 2022. PMID: 35313552 Free PMC article.
PURPOSE: MYB proto-oncogene like 2 (MYBL2) is a member of the MYB family of transcription factor genes and overexpressed in many cancers. We investigated the role of MYBL2 in the malignant progression of prostate cancer (PCa) and its relationship with …
PURPOSE: MYB proto-oncogene like 2 (MYBL2) is a member of the MYB family of transcription factor genes and overexpressed in many c …
362 results